Transition to an oral anticoagulant in patients with heparin-induced thrombocytopeniaBARTHOLOMEW, John R.Chest. 2005, Vol 127, Num 2, pp 27S-34S, issn 0012-3692, SUPArticle

Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formationYOUNG, Guy; YONEKAWA, Karyn E; NAKAGAWA, Peggy A et al.Blood coagulation & fibrinolysis. 2007, Vol 18, Num 2, pp 97-103, issn 0957-5235, 7 p.Article

Management of heparin resistance during cardiopulmonary bypass: The effect of five different anticoagulation strategies on hemostatic activationKOSTER, Andreas; FISCHER, Thomas; GRUENDEL, Marcus et al.Journal of cardiothoracic and vascular anesthesia. 2003, Vol 17, Num 2, pp 171-175, issn 1053-0770, 5 p.Article

Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?DICKNEITE, Gerhard; HOFFMAN, Maureane.Thrombosis and haemostasis. 2014, Vol 111, Num 2, pp 189-198, issn 0340-6245, 10 p.Article

Bivalirudin : Current use of biologicals in thrombosis and haemostasisWARKENTIN, Theodore E; GREINACHER, Andreas; KOSTER, Andreas et al.Thrombosis and haemostasis. 2008, Vol 99, Num 5, pp 830-839, issn 0340-6245, 10 p.Article

Overview of Direct Thrombin Inhibitors in Clinical PracticeBOUNAMEAUX, Henri.Seminars in thrombosis and hemostasis. 2008, Vol 34, pp 12-17, issn 0094-6176, 6 p., SUP1Article

New anticoagulantsAGNELLI, Giancarlo; BECATTINI, Cecilia.Seminars in thrombosis and hemostasis. 2006, Vol 32, Num 8, pp 793-802, issn 0094-6176, 10 p.Article

Direct thrombin inhibitors for anticoagulationNUTESCU, Edith A; WITTKOWSKY, Ann K.The Annals of pharmacotherapy. 2004, Vol 38, Num 1, pp 99-109, issn 1060-0280, 11 p.Article

Emerging anticoagulant drugsBATES, Shannon M; WEITZ, Jeffrey I.Arteriosclerosis, thrombosis, and vascular biology. 2003, Vol 23, Num 9, pp 1491-1500, issn 1079-5642, 10 p.Article

Effects of vitamin K antagonist phenprocoumon on activated partial thromboplastin time measurement of direct thrombin inhibitorsFENYVESI, Tivadar; JÖRG, Ingrid; WEISS, Christel et al.Blood coagulation & fibrinolysis. 2004, Vol 15, Num 7, pp 605-611, issn 0957-5235, 7 p.Article

Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopeniaCALL, Jason T; DELIARGYRIS, Efthymios N; SANE, David C et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, Num 3, pp 297-304, issn 0094-6176, 8 p.Article

Treatment of heparin-induced thrombocytopenia : Is there a role for bivalirudin?SEYBERT, Amy L; COONS, James C; ZERUMSKY, Kristin et al.Pharmacotherapy. 2006, Vol 26, Num 2, pp 229-241, issn 0277-0008, 13 p.Article

New approaches to oral anticoagulation: Direct thrombin inhibitorsWEITZ, Jeffrey I.Thrombosis and haemostasis. 2009, Vol JUN, pp 11-15, issn 0340-6245, 5 p., HSConference Paper

Rationale for thrombin as an anticoagulant targetHUISMAN, Menno V.Thrombosis and haemostasis. 2008, pp 7-10, issn 0340-6245, 4 p., HSConference Paper

Hydroxyethyl starch enhances argatroban-mediated decreases in clot propagation and strength by diminishing thrombin-fibrinogen interactionsNIELSEN, Vance G; KIRKLIN, James K.Blood coagulation & fibrinolysis. 2007, Vol 18, Num 1, pp 49-54, issn 0957-5235, 6 p.Article

Measuring Direct Thrombin Inhibitors With Routine and Dedicated Coagulation Assays: Which Assay Is Helpful?CURVERS, Joyce; DE KERKHOF, Daan Van; STROOBANTS, An K et al.American journal of clinical pathology. 2012, Vol 138, Num 4, pp 551-558, issn 0002-9173, 8 p.Article

The mechanism of action of rivaroxaban ― an oral, direct Factor Xa inhibitor ― compared with other anticoagulantsMICHEL SAMAMA, Meyer.Thrombosis research. 2011, Vol 127, Num 6, pp 497-504, issn 0049-3848, 8 p.Article

The Anti-Inflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Inhibitors : Experimental and Clinical ObservationsHOPPENSTEADT, Debra A; JESKE, Walter; WALENGA, Jeanine M et al.Seminars in thrombosis and hemostasis. 2008, Vol 34, pp 97-102, issn 0094-6176, 6 p., SUP1Article

Anticoagulant therapy: basic principles, classic approaches and recent developmentsSINAURIDZE, Elena I; PANTELEEV, Mikhail A; ATAULLAKHANOV, Fazoil I et al.Blood coagulation & fibrinolysis. 2012, Vol 23, Num 6, pp 482-493, issn 0957-5235, 12 p.Article

Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness : ANTICOAGULATIONGULSETH, Michael P; WITTKOWSKY, Ann K; FANIKOS, John et al.Pharmacotherapy. 2011, Vol 31, Num 12, pp 1232-1249, issn 0277-0008, 18 p.Article

A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assaysCARLSSON, Stefan C; MATTSSON, Christer; ERIKSSON, Ulf G et al.Thrombosis research. 2005, Vol 115, Num 1-2, pp 9-18, issn 0049-3848, 10 p.Article

Comparison of Bivalirudin Dosing Strategies Using Total, Adjusted, and Ideal Body Weights in Obese Patients with Heparin-Induced ThrombocytopeniaTSU, Laura V; DAGER, William E.Pharmacotherapy. 2012, Vol 32, Num 1, pp 20-26, issn 0277-0008, 7 p.Article

Looking back into the future: desirudin in acute coronary syndromes and coronary stentingVRANCKX, Pascal; VALGIMIGLI, Marco; SERRUYS, Patrick et al.EuroIntervention. 2011, Vol 7, Num 2, pp 263-269, issn 1774-024X, 7 p.Article

The re-emergence of anticoagulation in coronary diseaseANTMAN, Elliott M.European heart journal supplements. 2004, Vol 6, Num B, pp B2-B8, issn 1520-765XArticle

Decreased argatroban clearance unaffected by hemodialysis in anasarcaDE DENUS, Simon; SPINLER, Sarah A.The Annals of pharmacotherapy. 2003, Vol 37, Num 9, pp 1237-1240, issn 1060-0280, 4 p.Article